马来酸依那普利叶酸片治疗H型高血压的系统评价

杜彪; 张杰; 谢星星; 周春阳; 杜扬

马来酸依那普利叶酸片治疗H型高血压的系统评价

Systematic Review of Enalapril-folic Acid Tablet in Treatment of H-type Hypertension

摘要

摘要: 目的系统评价马来酸依那普利叶酸片治疗H型高血压的临床疗效和安全性。方法计算机检索CNKI、维普、万方、PubMed、Medline、EMbase和相关数据库，辅以文献追溯、网上查询等方法，检索建库至2015年5月31日国内外公开发表的马来酸依那普利叶酸片治疗H型高血压随机对照研究，采用RevMan 5.0软件进行定量综合分析。结果共纳入17篇对照研究，合计H型高血压患者2 323例。其中14项研究介绍了SBP改变情况，结果显示：WMD=-6.73，95%CI：-10.13~-3.39，Z=3.93，P<0.05；14项研究介绍了DBP改变情况，结果显示：WMD=-6.76，95%CI：-10.23~-2.51，Z=5.96，P<0.05；17项研究介绍了Hcy改变情况，结果显示：WMD=-4.18，95%CI：-6.58~-3.03，Z=5.32，P<0.05；7项研究介绍了心脑血管事件发生情况，结果显示：OR=0.28，95%CI：0.18~0.43，Z=5.96，P<0.05。常见不良反应无显著性差异。结论马来酸依那普利叶酸片治疗H型高血压的疗效和安全性优于马来酸依那普利。

Abstract: OBJECTIVE To evaluate the clinical efficacy and safety of enalapril-folic acid in the treatment of H-type hypertension. METHODS Retrieved from CNKI, VIP, Wanfang database, PubMed, Medline and EMBase, RCTs about Enalapril-folie acid treatment of H-type hypertension were collected and evaluated by Cochrane systematic review. Meta-analysis was carried out by using RevMan 5.0 software. RESULTS The 17 studies were included, involving 2 323 patients. Meta-analysis showed that there was statistical significant between enalapril-folic acid and enalapril on SBP(WMD=-6.73, 95%CI: -10.13- -3.39, Z=3.93, P<0.05), DBP(WMD=-6.76, 95%CI: -10.23- -2.51, Z=5.96, P<0.05) and Hcy(WMD=-4.18, 95%CI: -6.58- -3.03, Z=5.32, P<0.05). The incidence of cardiovascular events in both group had significant difference (OR=0.28, 95%CI: 0.18-0.43, Z=5.96, P<0.05) and the common adverse reactions had no significant difference. CONCLUSION Enalapril-folic acid is more effective and safety than enalapril for treatment of H-type hypertension.

HTML全文

参考文献(1)

施引文献

资源附件(0)